TerminatedNCT01491490
Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine
Medication studyAges 18+United KingdomSchizophrenia
Understand this study
Who could participate?
Listed age limits: from 18 years.
- Listed locations
- Birmingham and 5 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateOctober 2011
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 2
- Sponsor
- GW Research Ltd
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom
- Age range
- Over 18 Years
- Official registry ID
- NCT01491490
- Official title
Show the full official title
A Randomised, Doubleblind,Placebo Controlled, Parallel Group, Pilot Study of 40:1 Ratio of Formulated GW42003 :GW42004 in the Treatment of Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine Treatment in Subjects With Functional Psychosis
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham · Leicester · Oxford
3 more locations
- South London
- Surrey
- West London
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is GW Research Ltd.
Does this study involve medication?
Yes. The study involves medication, including GWP42003 : GWP42004 (40:1) and Placebo.
Who can participate?
Listed age limits: from 18 years.
Is this study still recruiting?
The registry lists this study as terminated.
